Literature DB >> 19967540

[A comparative in vitro analysis of primary and immortalized keratocytes].

L Kagan1, P W Rieck.   

Abstract

BACKGROUND: The cultivation of primary keratocytes (HCKp) is difficult and influenced by a multitude of factors. In this study it was examined if immortalized keratocytes (HCKi) can replace HCKp in experiments and be useful in the development of a cornea construct.
METHODS: HCKp and HCKi were cultivated and incubated for 72 h with benzalkonium chloride (BAC) or cetrimide at concentrations of 40-0.1 microg/ml or 100-0.01 microg/ml. The vitality and the doubling time (tv) were measured.
RESULTS: Treatment with 40 or 4 microg/ml BAC as well as 100 or 10 microg/ml cetrimide led to cell death. The tv was shortened in HCKi especially in cells that were treated with BAC, but only HCKp showed a significant loss of vitality. In cells treated with cetrimide the tv increased significantly in both cell lines and no loss of vitality was detected from 0.1 microg/ml onwards in both cell lines.
CONCLUSION: HCKi are more resistant and proliferative than HCKp but they can be used in preliminary experiments as an alternative to primary cells in for example toxicity studies if the detectable differences between the two cell lines, such as the capacity for proliferation and reaction to agents are taken into consideration.

Entities:  

Mesh:

Year:  2010        PMID: 19967540     DOI: 10.1007/s00347-009-2003-4

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  21 in total

1.  Immortalization of human corneal endothelial cells using electroporation protocol optimized for human corneal endothelial and human retinal pigment epithelial cells.

Authors:  J Bednarz; M Teifel; P Friedl; K Engelmann
Journal:  Acta Ophthalmol Scand       Date:  2000-04

2.  Functional human corneal equivalents constructed from cell lines.

Authors:  M Griffith; R Osborne; R Munger; X Xiong; C J Doillon; N L Laycock; M Hakim; Y Song; M A Watsky
Journal:  Science       Date:  1999-12-10       Impact factor: 47.728

3.  A human corneal equivalent constructed from SV40-immortalised corneal cell lines.

Authors:  Michaela Zorn-Kruppa; Svitlana Tykhonova; Gazanfer Belge; Jürgen Bednarz; Horst A Diehl; Maria Engelke
Journal:  Altern Lab Anim       Date:  2005-02       Impact factor: 1.303

4.  Reconstruction of cornea in three-dimensional collagen gel matrix culture.

Authors:  Y Minami; H Sugihara; S Oono
Journal:  Invest Ophthalmol Vis Sci       Date:  1993-06       Impact factor: 4.799

5.  Characterization of SV40-transfected cell strains from rabbit keratocytes.

Authors:  P A Barry-Lane; S E Wilson; H D Cavanagh; W M Petroll; J V Jester
Journal:  Cornea       Date:  1997-01       Impact factor: 2.651

6.  Impact of short-term exposure of commercial eyedrops preserved with benzalkonium chloride on precorneal mucin.

Authors:  So-Hyang Chung; Su Kyung Lee; Stephen M Cristol; Eun Suk Lee; Dong Wook Lee; Kyoung Yul Seo; Eung Kweon Kim
Journal:  Mol Vis       Date:  2006-04-26       Impact factor: 2.367

7.  Effects of antiglaucoma drugs on cellular proliferation in cultured human corneal keratocytes.

Authors:  Kwou-Yeung Wu; Hwei-Zu Wang; Show-Jen Hong
Journal:  Kaohsiung J Med Sci       Date:  2006-03       Impact factor: 2.744

8.  Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro.

Authors:  Seung-Heon Cha; Jong-Soo Lee; Boo-Sup Oum; Chi-Dae Kim
Journal:  Clin Exp Ophthalmol       Date:  2004-04       Impact factor: 4.207

9.  Human corneal equivalent as cell culture model for in vitro drug permeation studies.

Authors:  S Reichl; J Bednarz; C C Müller-Goymann
Journal:  Br J Ophthalmol       Date:  2004-04       Impact factor: 4.638

10.  Comparative study on the cytotoxic effects of benzalkonium chloride on the Wong-Kilbourne derivative of Chang conjunctival and IOBA-NHC cell lines.

Authors:  E Brasnu; F Brignole-Baudouin; L Riancho; J-M Warnet; C Baudouin
Journal:  Mol Vis       Date:  2008-03-04       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.